![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30770-30777, October 22, 1999
,
,
From the Departments of
Physiology and
¶ Pharmacology University of Minnesota, Minneapolis, Minnesota
55455 and the § Section of Biochemistry, Molecular, and Cell
Biology, Cornell University, Ithaca, New York 14853
| |
ABSTRACT |
|---|
|
|
|---|
ADP-ribosyl cyclase synthesizes two
Ca2+ messengers by cyclizing NAD to produce cyclic
ADP-ribose and exchanging nicotinic acid with the nicotinamide group of
NADP to produce nicotinic acid adenine dinucleotide phosphate.
Recombinant Aplysia cyclase was expressed in yeast and
co-crystallized with a substrate, nicotinamide. x-ray crystallography
showed that the nicotinamide was bound in a pocket formed in part by a
conserved segment and was near the central cleft of the cyclase.
Glu98, Asn107 and Trp140 were
within 3.5 Å of the bound nicotinamide and appeared to coordinate it.
Substituting Glu98 with either Gln, Gly, Leu, or Asn
reduced the cyclase activity by 16-222-fold, depending on the
substitution. The mutant N107G exhibited only a 2-fold decrease in
activity, while the activity of W140G was essentially eliminated. The
base exchange activity of all mutants followed a similar pattern of
reduction, suggesting that both reactions occur at the same active
site. In addition to NAD, the wild-type cyclase also cyclizes
nicotinamide guanine dinucleotide to cyclic GDP-ribose. All mutant
enzymes had at least half of the GDP-ribosyl cyclase activity of the
wild type, some even 2-3-fold higher, indicating that the three
coordinating amino acids are responsible for positioning of the
substrate but not absolutely critical for catalysis. To search for the
catalytic residues, other amino acids in the binding pocket were
mutagenized. E179G was totally devoid of GDP-ribosyl cyclase activity,
and both its ADP-ribosyl cyclase and the base exchange activities were
reduced by 10,000- and 18,000-fold, respectively. Substituting Glu179 with either Asn, Leu, Asp, or Gln produced similar
inactive enzymes, and so was the conversion of Trp77 to
Gly. However, both E179G and the double mutant E179G/W77G retained
NAD-binding ability as shown by photoaffinity labeling with
[32P]8-azido-NAD. These results indicate that both
Glu179 and Trp77 are crucial for catalysis and
that Glu179 may indeed be the catalytic residue.
ADP-ribosyl cyclase was first discovered in sea urchin egg
extracts as an activity converting NAD to a Ca2+-releasing
metabolite, which was later identified as cyclic ADP-ribose (cADPR)1 (1, 2). Accumulating
evidence indicates cADPR is a Ca2+ messenger important in
regulating various cellular functions in a variety of species from
plant to human (reviewed in Refs. 3 and 4). Similarly, the cyclase has
since been shown to be ubiquitous and is particularly abundant in
Aplysia ovotestis (5-9). Sequence comparison reveals that
the Aplysia cyclase is homologous to antigens CD38 on human
lymphocytes and BST1/BP3 on bone marrow cells (10, 11). In addition to
sharing 25-30% sequence identity, there is also a perfect alignment
of the cysteines of the homologs. Subsequent work shows that all
members of the cyclase family are also functionally similar, since they
all are enzymes catalyzing the cyclization of NAD to cADPR (Refs. 12 and 13; reviewed in Refs. 14 and 15). More surprising is the discovery
that all these enzymes also can use NADP as a substrate and catalyze
the exchange of its nicotinamide group with nicotinic acid, producing
nicotinic acid adenine dinucleotide phosphate (16), which is capable of
activating a novel Ca2+ release mechanism that is totally
independent of that activated by cADPR or inositol trisphosphate (17).
This novel nicotinic acid adenine dinucleotide
phosphate-dependent mechanism was first shown to be present
in invertebrate eggs and oocytes (17, 18) and has recently been found
to be important in coordinating the hormonal Ca2+ signaling
functions in mouse pancreatic acinar cells (19), indicating that it is
likely to be also a signaling mechanism of general relevance.
It is uncommon that a single enzyme can use two different substrates
and produce two structurally and functionally distinct signaling
molecules. A model has been proposed to account for this novel
multiplicity in catalysis (15, 20-23). The salient feature of this
catalytic model is the proposal that a single intermediate is
responsible for cyclization, hydrolysis, and base exchange chemistries
of the cyclase family of enzymes. Experimental support for this model
has recently been provided (23). x-ray crystallography reveals that the
Aplysia cyclase is a bean-shaped molecule with a central
cleft (24). In solution as well as in the crystalline state, the
cyclase forms dimers from two monomers in a head-to-head fashion
enveloping a central cavity the size of a molecule of cADPR (24, 25).
This structural feature suggests that the active site of the enzyme may
be at the central region of the molecule. In this study, the
Aplysia cyclase was co-crystallized with nicotinamide, a
substrate for the base-exchange reaction. The active site of the enzyme
was identified and characterized by x-ray crystallography and
site-directed mutagenesis.
Expression of the Aplysia ADP-ribosyl Cyclase in Yeast--
The
Pichia expression vector pPICZ
Some of the mutant proteins were also expressed in the X-33 strain
(Invitrogen) of Pichia pastoris. This strain is isogenic to
the GS115 strain, except that it contains the native alcohol oxidase
AOX1 and HIS4 genes. The AOX1 gene
allows the yeast to metabolize methanol and grow to higher densities,
particularly during fermentation. The native histidine gene,
HIS4, facilitates production of endogenous histidine and
allows rapid growth of the yeast without any external supplementation
of histidine. The dominant selectable marker, Zeocin, also allows for
use of positive selection vectors pPICZ Production of Antibodies against the Aplysia ADP-ribosyl
Cyclase--
Polyclonal antibodies were produced in rabbits by Genosys
Biotechnologies, Inc. (The Woodlands, TX). The recombinant wild type
cyclase produced as described above was used as antigen. Antibodies
against the conserved region of the Aplysia cyclase were
also raised using a synthetic peptide, TLEDTLLGYL. Western blots were
visualized by chemiluminescence using a kit from Amersham Pharmacia Biotech.
Enzyme Assays--
The wild type or mutant cyclase (50-3,000
ng/ml) was incubated (2-120 min) at room temperature with various
concentrations of NAD (25-1,000 µM) or nicotinamide
guanine dinucleotide (NGD) (10-2,000 µM) at pH 7.8 buffered by 40 mM Tris-HCl. The total volume of the
reaction mixture was 0.12 ml, and the reaction was stopped by the
addition of SDS (0.17% final concentration). The reaction products
were analyzed by HPLC (BioCad) using either a Poros 10 HQ column (Roche
Molecular Biochemicals) or an AG MP-1 column (6.6 × 150 mm). The
resin AG MP-1 was obtained from Bio-Rad. The elution was performed
either using a gradient of NaCl (HQ column) or trifluoroacetic acid (AG
MP1 column) at a flow rate of 5 ml/min. The base exchange reaction was
similarly assayed at pH 4.5 in the presence of 50 mM
nicotinic acid and various concentrations of NADP (20-4,000
µM). Enzyme activities of the wild type and mutant
cyclases were measured, each using two or three different protein
preparations. The results shown are mean ± S.E. of 9-12
determinations. The Vmax and
Km values were obtained from double-reciprocal
plots, and the results shown are mean ± S.E. of at least five determinations.
Site-directed Mutagenesis of ADP-ribosyl Cyclase--
Primers
for the 5'- and 3'-ends of the cyclase cDNA were as follows: 1)
CYC-F2, hybridizing to the 5' region of mature soluble cyclase starting
with IVPTR ... and also generating an EcoRI restriction site, 5'-CAT GAA TTC ATC GTC CCC ACT CGC-3' and 2) CYC-R, hybridizing to the 3' region of cyclase as well as generating a NotI
site, 5'-AAT GCG GCC GCG AAA TTG GTA AAG AGC-3'. Amplification was
carried out using 0.5 unit of Vent polymerase (New England Biolabs),
280 µM dNTPs (New England Biolabs), and 0.4 µM primers in a 50.0-µl reaction. The mutations were
carried out in two sequential amplification steps. During the first
amplification, two fragments were generated. The primer CYC-F2 and an
antisense primer for a specific mutation were used to generate one
fragment, and the primer CYC-R and a sense primer for the same mutation
were used to generate the other. For both of these polymerase chain
reactions, the native cyclase sequence served as the template. The two
fragments were gel-purified and used for the second amplification,
during which the purified fragments served as the templates, and
primers CYC-F2 and CYC-R were used to generate the 0.77-kilobase pair
cyclase containing the mutation. The mutated cyclase was then
gel-purified, digested with EcoRI and NotI, and
ligated into a yeast expression vector that we had constructed
previously (27).
Some mutations were done using the QuickChange site-directed
mutagenesis kit obtained from Stratagene. The kit employs the high
fidelity PfuTurbo DNA polymerase and mutant oligonucleotide primers to replicate both strands of the supercoiled plasmid containing the insert. A mutated plasmid containing staggered nicks is generated. Following thermal cycling, the reaction mixture is treated with DpnI endonuclease, which digests hemimethylated parent DNA
leaving behind the nicked DNA containing the mutation of interest.
Plasmid DNA from most Escherichia coli strains is
dam-methylated and can be digested away with the
DpnI enzyme. This method eliminates the use of various
subcloning procedures necessary to generate mutants. The procedure only
takes 7 days, starting from the mutation reaction, to transforming
E. coli with the mutated DNA and purifying the resulting
SacI-digested DNA for use in yeast transformation.
Co-Crystallization of the Recombinant ADP-ribosyl Cyclase and
Nicotinamide--
Crystals were grown using the hanging drop method.
Crystallization conditions for the recombinant cyclase were initially
determined and optimized. These conditions were subsequently used to
co-crystallize the enzyme with nicotinamide. Co-crystals were obtained
using a reservoir solution containing 17% (w/v) polyethylene glycol (molecular weight of 4,000) and 0.1 M imidazole buffer (pH
7.5). The crystallization drops contained 2.5 µl of the reservoir
solution and 2.5 µl of concentrated protein (OD = 12 at 280 nm).
Crystallization trays were stored at 18 °C, and crystals displaying
thin rod-shaped morphology with a length typically of 0.5 mm generally
appeared within 7 days.
X-ray Structure Determination--
x-ray diffraction data were
collected from a single co-crystal using the A-1 station (
The diffraction data were collected using the 82 × 82-mm 2 K × 2 K Princeton CCD-based x-ray detector (29). The data indexed as a
triclinic lattice and extended to 2.4 Å, displaying a very high
anisotropic mosaicity, which varied from 1.75 to 3.5°. Data reduction
and scaling yielded a partially complete data set with a unit cell of
60.4 × 75.3 × 138.1 Å. The overall
Rsym for the data set was 6.8%, with the
highest resolution shell of 2.6-2.4 Å having a high
Rsym of 31%.
The x-ray structure of the nicotinamide-cyclase complex was solved by
molecular replacement using the program AMORE (30). A search model was
constructed from the previously determined dimeric structure of
ADP-ribosyl cyclase. Because the two cyclase monomers of this dimer
were built and refined independently, a modified dimer was constructed
using only the chain A monomer truncated at residue 247. Side chain
atoms were retained in the search model.
Four solutions to the rotation function were found. The translation
search using these orientations resulted in the position of four
individual dimers in the asymmetric unit of the unit cell. The
resulting positions of the four cyclase dimers displayed reasonable crystal packing contacts, suggesting that the solutions were correct. The four molecules were found to be independently positioned within the
asymmetric unit lacking noncrystallographic symmetry. This was verified
by calculating self-rotation functions using the program GLRF (31). The
best solution according to the AMORE statistics had a correlation
coefficient of 42.9 and an R-factor of 41.3.
The presence of four dimers in the asymmetric unit results in a
favorable Mathews coefficient of 2.59. The four dimers give a total
molecular mass of 240 kDa. The solvent content of the crystals is
calculated to be 53%.
Structure Refinement--
Residues 127-129 were mutated to
alanines in each of the eight monomers for subsequent check of the
quality and bias of electron density maps to be calculated. X-ray
structure factors were calculated using the position of the atoms
resulting from the placement of the four dimers in the unit cell, and
these resulting structure factors were refined against the measured
diffraction data. 5% of the reflections were set aside for calculating
the R-free parameter. Rigid body refinement was conducted
using the program X-PLOR (32) and all data between 8 and 3 Å. Because
the native monomeric structure is composed of two discrete domains (the
N-terminal domain consisting of residues 1-66 and residues 100-150,
the C-terminal domain consisting of residues 74-97 and residues
153-250), the refinement was carried out with each domain defined as a
rigid body. In addition, rigid body refinement was conducted with each
monomer defined as a rigid body. The approach where each monomer was
refined as two discrete domains gave the lower R-factor.
With an overall B-factor assigned as 20, the
R-factor after rigid body refinement was 36.3%.
Although no proper NCS relations are present in the crystal structure,
each domain of each monomer can be related to that of a reference
molecule by translation and rotation. In this manner, strict NCS
restraints (weight = 500 kcal/mol-Å2 in X-PLOR) were
applied to the domains of all of the monomers, thereby reducing the
number of parameters to be refined. Simulated annealing refinement was
conducted against all data between 8 and 2.4 Å, resulting in an
R-factor of 31.2% (R-free = 34.0%). Including a bulk solvent model and using all data between 20 and 2.4 Å in another cycle of simulated annealing refinement resulted in an
R-factor of 28.4% (R-free = 31.6%).
Finally, tightly restrained individual B-factor refinement
gave an R-factor of 24.6% (R-free = 28.0%).
Synthesis of [32P]8-Azido-NAD and Photoaffinity
Labeling--
The details of the synthesis were as we have described
previously (33, 34). Briefly, 8-azido-3'-AMP was phosphorylated with
[
Wild type or mutant cyclases (0.3 µg) were incubated on ice in
50-µl droplets containing 50 µM
[32P]8-azido-NAD (~530,000 cpm), 0-5 mM
X-ray Crystallography of the Aplysia ADP-ribosyl Cyclase--
We
have previously shown that nicotinamide, similar to nicotinic acid, can
serve as a substrate for the base exchange reaction (16). In this case,
the product is the same as the substrate (NAD or NADP), and the enzyme
appeared inhibited. However, the rapid exchange can be readily
demonstrated using radioactive substrate (16). That nicotinamide is a
substrate indicates that it should have affinity for the active site of
the cyclase. We thus crystallized the recombinant cyclase with
nicotinamide. The structure of the complex was refined using various
procedures as described under "Materials and Methods," giving an
R-factor of 24.6% (R-free = 28.0%).
Electron density maps calculated from these refined coordinates suggest
that there are additional atoms present in the crystal structure. None
of the maps were biased by substrate assignments, yet in the initial
unaveraged 2Fo
Fig. 1A shows the van der
Waals contact surface of a cyclase dimer with one monomer colored
light blue and the other dark blue. Each monomer was a bean-shaped molecule consisting of
two domains separated by a central cleft. The two monomers associated with each other in a head-to-head fashion forming a donut-like molecule
with a central cavity (24). We have previously shown by chemical
cross-linking and dynamic laser light scattering that the cyclase forms
dimers in solution as well (25).
The tentative assignment of the bound nicotinamide is shown in
yellow in Fig. 1A. The binding site was in a
pocket at the central cleft of the monomer and was very close to the
central cavity of the dimer. Nicotinamide was bound to each monomer.
The binding pocket of the monomer colored dark
blue was not visible, because it was on the other side of
the monomer. The cyclase has a stretch of six amino acids (TLEDTL) that
are highly conserved with CD38, a homolog that also possesses similar
enzymatic activities as the cyclase (10, 12). This conserved region
formed part of the binding pocket and is shown in orange in
Fig. 1A.
Fig. 1B shows the three amino acids in the binding pocket
that were closest to the placement of the bound nicotinamide
(yellow) and appeared to complex the bound substrate. These
three residues were Trp140 (2.8 Å), Glu98 (3.5 Å), and Asn107 (3.1 Å). The conserved sequence is shown
as orange sticks, and Glu98 is part
of this sequence. Trp140, although not in the conserved
region, is nevertheless conserved among two species of the cyclase and
three species of CD38 (24). Asn107, on the other hand, is
not a conserved residue. If these amino acids are indeed responsible
for substrate binding, their alteration by site-directed mutagenesis
should result in reduction or elimination of the enzymatic activities
of the cyclase.
Site-directed Mutagenesis of the ADP-ribosyl Cyclase--
Various
mutations of the three amino acids closest to the bound nicotinamide
were produced, and the resulting mutant cyclases were expressed in
yeast as secretory proteins. The yeast media containing the mutant
proteins were dialyzed and purified by treatment with an anion exchange
resin (DEAE), which removed nondialyzable contaminants in the yeast
media. SDS-polyacrylamide gel electrophoresis showed that the
preparations of the mutant proteins after the DEAE treatment contained
essentially a single protein with molecular weight of about 29,000, similar to that of the wild type protein (Fig.
2). Examples of Western analysis of some
of the mutant proteins are shown in Fig. 2. All mutant proteins are
recognized by the polyclonal antibody against the wild type cyclase. On
the other hand, the antibody raised against the conserved peptide
(anti-ConPep) recognized the wild type, N107G, and W140G proteins but
not the mutant proteins E98L and E98G. Since Glu98 is one
of the amino acids in the conserved sequence, its change to leucine or
glycine is expected to render the mutant proteins unrecognizable by the
antipeptide antibody. The DNA from the regions containing the cyclase
insert in all four mutants was amplified by the polymerase chain
reaction using appropriate primers. The sequence results confirmed that
they harbored the correct mutations (Fig. 2, lower
panel).
Fig. 3 shows that substitution of
Glu98 with either Gln, Gly, Leu, or Asn resulted in a
16-222-fold decrease in the rate of cADPR synthesis as compared with
the wild type cyclase, indicating that Glu98 is important
for catalysis. The large decrease in activity is likely to be due to
the elimination of the negative charge on Glu98 by all
these mutations. The size of the substituting amino acids appears to
have a secondary effect on the activity. The mutant with the
conservative substitution by Gln, which is similar in size to Glu, had
only about 6% of the activity of the wild type enzyme. Smaller side
chains such as Leu produced a slightly larger decrease in activity. The
conversion to glycine (E98G), which is equivalent to deleting the side
chain of the glutamate, produced similar inhibition. Much more
destructive is substituting with a residue only slightly smaller than
Gln, such as Asn, which resulted in more than 200-fold decrease in
activity. It is unlikely that the inhibitory effect of the mutation was
due to nonspecific alterations of the structure of the enzyme, since
similar decreases were seen with such conservative substitutions as Asn
and Gln, which are generally considered to have minimal effect on
protein structures. More likely is that the enzyme activity has an
exquisitely specific requirement for both the charge and size of the
side chain at the 98-position, and any alteration would result in a
decrease in activity.
Table I summarizes and compares the
enzymatic parameters of several mutant cyclases with the wild type. Of
the three amino acids that complex the nicotinamide, Trp140
is the most critical to the cyclase activity. It is closest to the
bound nicotinamide, and its conversion to glycine resulted in a
4,648-fold decrease in activity. Asn107 is the least
critical; only a 2-fold decrease in activity was measured for the
mutant N107G. Asp99 is next to Glu98 and is
similarly charged. It is also in the highly conserved sequence, TLEDTL.
Nevertheless, its conversion to glycine produced much less pronounced
effect on the cyclase activity, only a 10-fold decrease. These results
indicate that the effect of the site-directed mutagenesis is
residue-specific and that Trp140 is the most critical
residue for the cyclase activity.
In addition to comparing the maximal cyclase activity at high substrate
concentration (Vmax values), Table I also lists
Vmax/Km ratios of the wild
type and mutants. The Michalis-Menten model predicts that at low
substrate concentrations the enzyme activity is proportional to the
substrate concentration and the proportionality constant is the
Vmax/Km ratio. The pattern of
changes of the ratios follows that of the Vmax
values, indicating that the mutant cyclases had lower activity at both
limits of high and low substrate concentration. The kinetic parameters
for W140G were not determined because its activity was too low. The
value shown in Table I was measured at 1 mM NAD, which
should be approximately the maximal activity.
Fig. 4 compares the cyclase activity with
the base exchange activity of five of the mutants. The pattern of
inhibition of both activities was similar. The mutant W140G had the
least cyclase and exchange activity, while N107G had the most. The
mutation thus affected both enzymatic activities similarly, suggesting that the same active site is responsible for catalyzing both
reactions.
We have previously shown that the wild type cyclase can also use NGD,
an analog of NAD, as substrate and cyclize it to cyclic GDP-ribose
(cGDPR), a fluorescent analog of cADPR (21, 36). Table
II compares the GDP-ribosyl cyclase
activities of the wild type and the mutants. It can be seen that,
contrary to the large decrease in the ADP-ribosyl cyclase activity
(cf. Table I), all mutant cyclases retained substantial
GDP-ribosyl cyclase activity. Indeed, both Glu98 mutants
had activity 2-3-fold higher than the wild type. Even the W140G
mutant, which only had residual ADP-ribosyl cyclase activity (Table I),
had substantial GDP-ribosyl cyclase activity. Its Km
value, however, was close to 40-fold higher. This disparity of the
effect of the mutations on the two enzyme activities suggests that
Glu98 and Trp140 may be important mainly in the
positioning of the substrate and that the binding of NGD and NAD may
involve different amino acid residues. The two amino acids thus may not
be directly participating in catalysis.
To search for the catalytic residues, other amino acids that make up
the binding pocket (cf. Fig. 1, A and
B) were mutagenized. Table III
shows that the mutant cyclase, E179G, was totally devoid of GDP-ribosyl
cyclase activity, and both its ADP-ribosyl cyclase and the base
exchange activities were reduced by more than 10,000- and 18,000-fold,
respectively. Conversion of Trp77 to glycine likewise
resulted in large decreases in all three enzymatic activities as
compared with the wild type cyclase. Furthermore, all enzymatic
activities were eliminated in the double mutant, W77G/E179G. Indeed,
the enzymatic activities of these mutant cyclases were so low that it
was difficult to obtain reliable measurements at lower substrate
concentrations. The results listed in Table III were thus measured only
at a high substrate concentration so that the rates were close to the
Vmax values of the respective enzymatic
activities. These results indicate that Glu179 and also
Trp77 are most likely the catalytic residues.
The critical importance of Glu179 was further shown by
substituting it with various other residues. As shown in Table
IV, all substitutions resulted in
inactivation of the enzyme. This was true also for the highly
conservative substitution with residues such as Gln, Asn, or even Asp.
Although the substitution with Asp maintained the charge, the size of
the side chain was smaller. The importance of size was also seen in the
large differences in activity from changing Glu98 to Asn as
compared with changing it to Gln (Fig. 3).
Although mutations at Glu179 and Trp77 produced
inactive enzymes, the mutant cyclases did maintain the ability to bind
NAD. Fig. 5 shows the photoaffinity of
the wild type and the mutant cyclases. The labeling was competitively
inhibited by increasing concentrations of NAD, indicating the labeling
was specific. Even the double mutant, which had no observable enzyme
activity (Table III), retained the NAD-binding ability. The
half-maximal inhibition was about 0.1 mM NAD for the wild
type and about 0.5 mM NAD for E179G and the double mutant.
That NAD was less effective in competing in the case of the mutants
suggests that the affinity of the mutant active sites for NAD is less
than the wild type. As shown in the inset of Fig. 5
(lane 1), in the absence of NAD, the labeling intensity of E179G and the double mutant was actually higher than the
wild type although the same amounts of protein were loaded onto the gel
and the labeling was performed under identical conditions. In fact,
quantification of the phosphor image shows that the labeling intensity
of E179G and the double mutant was 2- and 1.5-fold higher, respectively, than that of the wild type. These results indicate that
the inactivating effect of the mutations is not due to nonspecific alteration of the protein structure, which would expectedly destroy the
substrate binding ability of the enzyme.
The Structure of the Active Site of ADP-ribosyl Cyclase--
Fig.
1C shows a stereo view of the active site. The van der Waals
contact surface of the site is shown with the three most critical amino
acids, Trp140, Trp77, and Glu179,
rendered as space-filling models. The active site is in a pocket with
Glu179 deep inside the pocket, while Trp140 and
Trp77 line the rim of the pocket, one on each side. The
carboxyl oxygen atoms of Glu179 and the carbonyl oxygen
atom of Trp77, which are likely to participate directly in
catalysis, are shown in red. The bound nicotinamide is shown
in yellow. The aromatic ring of Trp140 is close
to, and appears to position, the bound nicotinamide, presumably through
hydrophobic interaction.
In this study, the active site of the cyclase was first identified
by co-crystallizing the cyclase with nicotinamide, a substrate of the
base exchange reaction. X-ray crystallography allowed the unambiguous
identification of the three amino acids in the cyclase that were
closest to the bound nicotinamide. To determine if they are the
catalytic residues, site-directed mutagenesis was used to alter these
amino acids. Although large decreases in the cyclase and the base
exchange activities were observed in the mutants, they nevertheless
retained substantial GDP-ribosyl cyclase activity. The results suggest
that the residues are most likely important in positioning of the
substrate but may not be directly participate in catalysis. Indeed, our
previous results have suggested that NAD and NGD may bind to the active
site differently. Since the site of cyclization in cADPR is at the
N1-position of the adenine, but is at the N7-position of the guanine in
cGDPR (36, 37), the purine ring must thus be in the
anti-configuration during cyclization in the case of NGD but
is in the syn-configuration in the case of NAD. These
structural differences of the products are consistent with the idea
that different amino acid residues may be involved in binding of the
two substrates.
It is reasonable to expect that the catalytic residues should be closer
to the substrate, NAD, instead of nicotinamide. It is technically
difficult to co-crystallize the cyclase with NAD because it can quickly
convert NAD to its product, cADPR, which may not have much affinity for
the active site of the cyclase. Nevertheless, it is logical to assume
that the NAD-binding site must be close to the nicotinamide-binding
site. Asp99 was a good candidate, since it was next to
Glu98, one of the coordinating residues for the bound
nicotinamide, and it was also in the highly conserved sequence.
Conversion of Asp99 to glycine produced, however, less
inhibition of the enzymatic activities than the mutant, E98G. To search
for the catalytic residues, other residues were explored. x-ray
crystallography showed that the nicotinamide-binding site is in a
pocket formed in part by the conserved sequence (cf. Fig. 1,
A and B). Deep inside this binding pocket is
another acidic residue, Glu179, which is conserved among
various species of cyclases, CD38, and BST-1 (24). Indeed, its
conversion to glycine resulted in complete elimination of the
GDP-ribosyl cyclase activity and an over 10,000-fold decrease in both
the ADP-ribosyl cyclase and the base exchange activities. These results
are consistent with Glu179 being a catalytic residue.
It has previously been proposed that a single intermediate is
responsible for the cyclization and the base exchange activities of the
cyclase (15, 20-23). According to this model, the cyclase binds NAD in
a folded conformation so that the ends can be brought together for
cyclization (15). The next step is likely to be the release of
nicotinamide and the formation of an intermediate, which is proposed to
be an oxocarbonium ion. This ionic intermediate has been proposed also
for a variety of other NAD-utilizing enzymes, such as diphtheria and
Clostridium botulinum C2 toxins, and orotate phosphoribosyltransferase (38-40). The cationic oxocarbonium
intermediate is unstable and must be stabilized by anionic residues
nearby. A glutamate, which is also the catalytic residue, was found to perform such a function in both diphtheria and C. botulinum
C2 toxins. This is consistent with our results indicating that the catalytic residue of the cyclase is also a glutamate,
Glu179. In the case of orotate phosphoribosyltransferase,
an aspartate serves a similar function.
Conversion of Trp77, another residue in the
nicotinamide-binding pocket of the cyclase, to glycine resulted in a
similar degree of reduction of enzymatic activities as mutagenizing
Glu179. X-ray crystallography shows that both
Trp77 and Trp140 line the rim of the binding
pocket, one on each side. Trp140 is in close proximity to
the bound nicotinamide, suggesting that it is important in positioning
the substrate. Trp77 may serve a similar function in
positioning the substrate NAD through hydrophobic interaction. Another
important function that the two tryptophan residues may serve is to
curtail the access of water to the catalytic site through the
hydrophobicity of their side chains. Inaccessibility of water to the
active site would ensure that the nucleophilic attack of the
oxocarbonium intermediate by the 1-nitrogen of the adenine is the
dominant reaction, leading to the cyclization of NAD to produce cADPR.
Access of water to the active site, on the other hand, would lead to
the formation of ADP-ribose through hydrolysis, which is the dominant
reaction catalyzed by CD38 (12, 41).
Another notable structural feature of the active site shown in this
study is its close proximity to the central cavity formed by the two
monomer cyclase molecules (Fig. 1A). The size of the central
cavity is similar to the dimensions of a molecule of cADPR. This
suggests the possibility that the central cavity may serve as a
channel, through which the product of catalysis, cADPR, can pass (4). A
recent report has now provided strong experimental support that a
homolog of the cyclase, CD38, may indeed function as such a novel
transporter of cADPR (42). It is shown that when resealed
right-side-out red cell ghosts that contain ecto-CD38 are incubated
with NAD (or NGD), active transport of cADPR (or cGDPR) occurs,
generating a concentration gradient of the product 10-80-fold higher
inside than outside (42). Inhibition of the enzymatic activity of CD38
by mercaptoethanol blocks the process. Similar active transport of the
enzymatic products is seen with purified CD38 reconstituted into
liposomes (42). That CD38 is a transporter capable of active
translocation of its enzymatic products across membranes provides a
novel explanation of how a surface antigen with its catalytic domain on
the outside of the cells can participate in intracellular
Ca2+ signaling (43). The structural features of the active
site of the cyclase shown in this study are consistent with such a proposal.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
A (Invitrogen, Carlsbad,
CA) was used, and the construct consists of cloning the wild type or
mutant cyclase in frame with the yeast mating
-factor signal sequence. The details of the construct were as we have described previously (26-28). The tightly controlled alcohol oxidase promotor was used to regulate the expression of the construct. Yeast (GS115 strain) transfected with the construct was grown in a fermentation bioreactor, and expression was induced by methanol. The expressed cyclase was secreted as a soluble protein in the fermentation medium,
and as much as 0.3 g/liter could be obtained (26, 27). Endogenous
proteolytic enzymes that normally are responsible for processing the
prepro-
-mating factor also removed the
-factor signal sequence
from the expressed cyclase.
A. With this vector the
transformation efficiency was nearly 100%, and no revertants were
detected. After a 5-day induction with methanol in a standard culture
tube, the yeast produced and secreted up to 40 µg/ml of the mutant
cyclase in the culture medium. A 10-ml culture provides more than
enough protein for all of the enzymatic characterizations, and a
bioreactor is not needed.
= 0.919 Å) at the Macromolecular Diffraction Facility at the Cornell
High Energy Synchrotron Source (MacCHESS). To reduce radiation damage,
the crystal was cooled to liquid nitrogen temperature. Prior to this,
the crystal was placed in a cryosolvent containing 22% polyethylene
glycol 4000 to prevent ice formation within the crystalline lattice.
-32P]ATP using polynucleotide kinase (U.S.
Biochemical Corp.). The resulting 8-azido-[5'-32P]3'-AMP
was converted to 8-azido-[5'-32P]AMP using nuclease P1
(U.S. Biochemical Corp.) and subsequently coupled to
-nicotinamide
mononucleotide using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. This procedure produced the radioprobe with high specific activity suitable for photoaffinity labeling (33, 34). Nonradioactive 8-azido-NAD was synthesized by coupling 8-azido-AMP with
-nicotinamide mononucleotide using the same carbodiimide reaction.
-NAD, and 0.5 mM
-NAD. The droplets were exposed to
160 mJ of ultraviolet light energy (~45 s) in a Stratalinker
chamber (Stratagene, La Jolla, CA). Pilot experiments showed that this
amount of UV energy produced optimal labeling without detectable
protein-protein cross-linking.
-NAD is not a substrate for the
cyclase (5) and was included in all samples to reduce potential
nonspecific labeling. Samples were analyzed by SDS-polyacrylamide gel
electrophoresis, and the radioactivity associated with the proteins was
measured using a phosphor imager (Packard, Meriden, CT). The phosphor
images were collected at 16-bit resolution for quantitative analyses but reduced to 8-bit for printout.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Fc and
Fo
Fc maps and all subsequent
maps, strong peaks appeared where the assignments had been made. Before
map averaging, the peaks were around 2.75
in the
Fo
Fc map. After 8-fold
averaging using the RAVE programs (35), the peaks were as large as 6
. In particular, between Glu98 and Trp140
there was strong density of the shape of a six-member ring resembling nicotinamide.

View larger version (106K):
[in a new window]
Fig. 1.
Structure of the active site of ADP-ribosyl
cyclase. The recombinant Aplysia cyclase was
co-crystallized with nicotinamide. A, the van der Waals
contact surface of the dimeric form of the cyclase is shown. The two
monomers are colored light and dark blue, respectively. The bound nicotinamide is shown in
yellow, and the conserved sequence that makes up part of the
active site pocket is shown in orange. B, a
close-up view of the bound nicotinamide (yellow). The three
amino acids that are closest to the bound nicotinamide are shown as
space-filling models. Two carbon atoms (green) in the
aromatic ring of Trp140, the carbonyl oxygen
(red) in the side chain of Asn107, and a
carboxyl oxygen (red) in Glu98 are the atoms
closest to the bound nicotinamide. The conserved sequence of the
cyclase is shown as orange sticks.
Thin lines in the background represent
the rest of the cyclase dimer, light blue for one
monomer and orange for the other. C, a stereo
view of the active site pocket. The bound nicotinamide is shown in
yellow. The three most critical amino acids are shown as
space-filling models. Carbon atoms are shown in green,
oxygen atoms in red, and nitrogen atoms in dark blue. The other monomer of the cyclase dimer is represented
as blue sticks visible on the right.
The rendering of the crystallographic data was done using the program
MOLMOL (44).

View larger version (86K):
[in a new window]
Fig. 2.
Immunoblot and DNA sequence analyses of the
mutant cyclases produced by site-directed mutagenesis. The
upper panel shows the immunoblots of the wild
type (WT) and various mutant cyclases, which were stained to
reveal protein. About 1 µg of protein was used in each
lane. Standard proteins with molecular weights of 45,000, 31,000, and 21,500 are in lanes labeled Std. One
blot was probed with an antibody raised against the conserved sequence
(antiConPep). A duplicate blot was probed with an antibody
raised against the recombinant wild type cyclase
(antiCyclase). The lower panel lists
the DNA sequences of the mutants. The specific nucleotide changes
introduced by site-directed mutagenesis are
underlined.

View larger version (39K):
[in a new window]
Fig. 3.
Effects of site-directed mutagenesis on the
ADP-ribosyl cyclase activity. The rate of cADPR production of the
mutant cyclases was measured at 960 µM NAD by HPLC as
described under "Materials and Methods" and compared with that of
the wild type. The cyclase activity of the wild type was 0.79 ± 0.05 mmol/mg/min.
Effects of site-directed mutagenesis on Aplysia ADP-ribosyl cyclase
activity

View larger version (26K):
[in a new window]
Fig. 4.
Comparison of the effects of site-directed
mutagenesis on the ADP-ribosyl cyclase and the base exchange
activities. The Vmax values of the two
activities of the mutants were compared with those of the wild type. A
similar pattern of inhibiton on the two enzyme activities is exhibited
by the five different mutants. The conversion of Trp140 to
glycine (W140G) produced the most inhibition of both enzyme activities,
while the conversion of Asn107 to glycine (N107G) produced
the least. The Vmax value of the ADP-ribosyl
cyclase activity of the wild type (WT) was measured to be
0.95 ± 0.19 mmol/mg/min (see Table I), and the
Vmax value of the base exchange activity of WT
was about 0.35 ± 0.07 mmol/mg/min (see Table III).
Effects of site-directed mutagenesis on GDP-ribosyl cyclase activity
Identification of the catalytic amino acid residues of the
ADP-ribosyl cyclase by site-directed mutagenesis
Inactivation of ADP-ribosyl cyclase activity by substituting
Glu179 with other amino acid residues

View larger version (36K):
[in a new window]
Fig. 5.
Photoaffinity labeling of the wild type and
mutant cyclases using [32P]8-azido-NAD. The labeled
proteins (~6 µg/lane) were analyzed by SDS-polyacrylamide gel
electrophoresis, and the radioactivity associated with the proteins was
visualized by a phosphor imager. The phosphor images were
quantitatively analyzed at 16-bit resolution. The inset
shows images of the proteins labeled with 50 µM
[32P]8-azido-NAD alone (lane 1) and
in the presence of 0.1 mM (lane 2),
0.5 mM (lane 3), 1 mM
(lane 4), and 5 mM (lane 5) NAD. The resolution of the images shown in the
inset was reduced to 8-bit.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Richard Graeff for critical reading of the manuscript. X-ray diffraction was conducted at CHESS using the MacCHESS facility.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health (NIH) Grants HD17484 (to H. C. L.) and DA11806 (to T. F. W.). CHESS is supported by National Science Foundation Grant DMR-9311772, and MacCHESS is supported by NIH Grant RR-01646.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Physiology, 435 Delaware St. SE, 6-255 Millard Hall, University of
Minnesota, Minneapolis, MN 55455. Tel.: 612-625-7120 (office) or
612-625-4641 (laboratory); Fax: 612-625-0991 (office) or 612-625-8408 (department); E-mail: leehc@maroon.tc.umn.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: cADPR, cyclic ADP-ribose; NGD, nicotinamide guanine dinucleotide; HPLC, high pressure liquid chromatography.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Lee, H. C.,
Walseth, T. F.,
Bratt, G. T.,
Hayes, R. N.,
and Clapper, D. L.
(1989)
J. Biol. Chem.
264,
1608-1615 |
| 2. |
Clapper, D. L.,
Walseth, T. F.,
Dargie, P. J.,
and Lee, H. C.
(1987)
J. Biol. Chem.
262,
9561-9568 |
| 3. | Lee, H. C. (1996) Rec. Prog. Horm. Res. 51, 355-388 |
| 4. |
Lee, H. C.
(1997)
Physiol. Rev.
77,
1133-1164 |
| 5. | Lee, H. C., and Aarhus, R. (1991) Cell Regul. 2, 203-209[Medline] [Order article via Infotrieve] |
| 6. | Lee, H. C., and Aarhus, R. (1993) Biochim. Biophys. Acta 1164, 68-74[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Rusinko, N.,
and Lee, H. C.
(1989)
J. Biol. Chem.
264,
11725-11731 |
| 8. | Hellmich, M. R., and Strumwasser, F. (1991) Cell Regul. 2, 193-202[Medline] [Order article via Infotrieve] |
| 9. | Glick, D. L., Hellmich, M. R., Beushausen, S., Tempst, P., Bayley, H., and Strumwasser, F. (1991) Cell Regul. 2, 211-218[Medline] [Order article via Infotrieve] |
| 10. | States, D. J., Walseth, T. F., and Lee, H. C. (1992) Trends Biochem. Sci. 17, 495[Medline] [Order article via Infotrieve] |
| 11. | Itoh, M., Ishihara, K., Tomizawa, H., Tanaka, H., Kobune, Y., Ishikawa, J., Kaisho, T., and Hirano, T. (1994) Biochem. Biophys. Res. Commun. 203, 1309-1317[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Howard, M.,
Grimaldi, J. C.,
Bazan, J. F.,
Lund, F. E.,
Santos-Argumedo, L.,
Parkhouse, R. M.,
Walseth, T. F.,
and Lee, H. C.
(1993)
Science
262,
1056-1059 |
| 13. | Hirata, Y., Kimura, N., Sato, K., Ohsugi, Y., Takasawa, S., Okamoto, H., Ishikawa, J., Kaisho, T., Ishihara, K., and Hirano, T. (1994) FEBS Lett. 356, 244-248[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Lee, H. C., Graeff, R., and Walseth, T. F. (1995) Biochimie (Paris) 77, 345-355[Medline] [Order article via Infotrieve] |
| 15. | Lee, H. C., Graeff, R. M., and Walseth, T. F. (1997) Adv. Exp. Med. Biol. 419, 411-419[Medline] [Order article via Infotrieve] |
| 16. |
Aarhus, R.,
Graeff, R. M.,
Dickey, D. M.,
Walseth, T. F.,
and Lee, H. C.
(1995)
J. Biol. Chem.
270,
30327-30333 |
| 17. |
Lee, H. C.,
and Aarhus, R.
(1995)
J. Biol. Chem.
270,
2152-2157 |
| 18. |
Albrieux, M.,
Lee, H. C.,
and Villaz, M.
(1998)
J. Biol. Chem.
273,
14566-14574 |
| 19. | Cancela, J. M., Churchill, G. C., and Galione, A. (1999) Nature 398, 74-76[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Kim, H., Jacobson, E. L., and Jacobson, M. K. (1993) Biochem. Biophys. Res. Commun. 194, 1143-1147[CrossRef][Medline] [Order article via Infotrieve] |
| 21. |
Graeff, R. M.,
Walseth, T. F.,
Fryxell, K.,
Branton, W. D.,
and Lee, H. C.
(1994)
J. Biol. Chem.
269,
30260-30267 |
| 22. |
Muller-Steffner, H. M.,
Augustin, A.,
and Schuber, F.
(1996)
J. Biol. Chem.
271,
23967-23972 |
| 23. | Sauve, A. A., Munshi, C., Lee, H. C., and Schramm, V. L. (1998) Biochemistry 37, 13239-13249[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Prasad, G. S., McRee, D. E., Stura, E. A., Levitt, D. G., Lee, H. C., and Stout, C. D. (1996) Nat. Struct. Biol. 3, 957-964[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Munshi, C., Baumann, C., Levitt, D., Bloomfield, V. A., and Lee, H. C. (1998) Biochim. Biophys. Acta 1388, 428-436[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Munshi, C. B., Fryxell, K. B., Lee, H. C., and Branton, W. D. (1997) Methods Enzymol. 280, 318-330[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Munshi, C., and Lee, H. C. (1997) Protein Expression Purif. 11, 104-110[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Hussain, A. M. M., Lee, H. C., and Chang, C. F. (1998) Protein Expression Purif. 12, 133-137[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Thiel, D. J., Ealick, S. E., Tate, M. W., Gruner, S. M., and Eikenberry, E. F. (1996) Rev. Sci. Instrum. 67, 1-4[CrossRef] |
| 30. | Navasa, J. (1994) Acta Crystallogr. Sec. A 50, 157-167[CrossRef] |
| 31. | Tong, L., and Rossmann, M. G. (1997) Methods Enzymol. 276, 594-611[Medline] [Order article via Infotrieve] |
| 32. | Brunger, A. T. (1992) X-PLOR, version 3.1 , Yale University Press, New Haven, CT |
| 33. |
Walseth, T. F.,
Aarhus, R.,
Kerr, J. A.,
and Lee, H. C.
(1993)
J. Biol. Chem.
268,
26686-26691 |
| 34. | Walseth, T. F., Aarhus, R., Gurnack, M. E., Wong, L., Breitinger, H.-G. A., Gee, K. R., and Lee, H. C. (1997) Methods Enzymol. 280, 294-305[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Jones, T. A. (1992) in Molecular Replacement (Dodson, E. J. , Gover, S. , and Wolf, W., eds) , pp. 91-105, SERC Daresbury Laboratory, Warrington, UK |
| 36. | Graeff, R. M., Walseth, T. F., Hill, H. K., and Lee, H. C. (1996) Biochemistry 35, 379-386[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Lee, H. C., Aarhus, R., and Levitt, D. (1994) Nat. Struct. Biol. 1, 143-144[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Bell, C. E., and Eisenberg, D. (1996) Biochemistry 35, 1137-1149[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Tao, W., Grubmeyer, C., and Blanchard, J. S. (1996) Biochemistry 35, 14-21[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Barth, H.,
Preiss, J. C.,
Hofmann, F.,
and Aktories, K.
(1998)
J. Biol. Chem.
273,
29506-29511 |
| 41. |
Kim, H.,
Jacobson, E. L.,
and Jacobson, M. K.
(1993)
Science
261,
1330-1333 |
| 42. |
Franco, L.,
Guida, L.,
Bruzzone, S.,
Zocchi, E.,
Usai, C.,
and Flora, A. D.
(1998)
FASEB J.
12,
1507-1520 |
| 43. | Deflora, A., Guida, L., Franco, L., and Zocchi, E. (1997) Int. J. Biochem. Cell Biol. 29, 1149-1166[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Koradi, R., Billeter, M., and Wuthrich, K. (1996) J. Mol. Graphics 14, 51-55[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology Physiol Rev, July 1, 2008; 88(3): 841 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Graeff, Q. Liu, I. A. Kriksunov, Q. Hao, and H. C. Lee Acidic Residues at the Active Sites of CD38 and ADP-ribosyl Cyclase Determine Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Synthesis and Hydrolysis Activities J. Biol. Chem., September 29, 2006; 281(39): 28951 - 28957. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Lee Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-mediated Calcium Signaling J. Biol. Chem., October 7, 2005; 280(40): 33693 - 33696. [Full Text] [PDF] |
||||
![]() |
D. A. Deshpande, T. A. White, S. Dogan, T. F. Walseth, R. A. Panettieri, and M. S. Kannan CD38/cyclic ADP-ribose signaling: role in the regulation of calcium homeostasis in airway smooth muscle Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L773 - L788. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. DE FLORA, E. ZOCCHI, L. GUIDA, L. FRANCO, and S. BRUZZONE Autocrine and Paracrine Calcium Signaling by the CD38/NAD+/Cyclic ADP-Ribose System Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 176 - 191. [Abs |